

Diagnostics Evaluation Series

No.4

Visceral Leishmaniasis Rapid Diagnostic Test Performance



**World Health
Organization**



**For research on
diseases of poverty**
UNICEF • UNDP • World Bank • WHO

WHO Library Cataloguing-in-Publication Data

Visceral leishmaniasis rapid diagnostic test performance.

1. Leishmaniasis, Visceral - diagnosis. 2. Leishmaniasis, Visceral - prevention and control. 3. Antibodies, Protozoan - analysis. 4. Reagent strips - diagnostic use. 5. Immunologic tests - utilization. 6. Sensitivity and specificity. I. World Health Organization. II. UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

ISBN 978 92 4 150223 8

(NLM classification: WC 175)

**Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2011
All rights reserved.**

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases. This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders. Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

WHO, including TDR, make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard. Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR. WHO, including TDR, accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Reference to any company or product in this report, particularly in any of the figures and tables listed on pages 21-23, 25-27 & 36-43, does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) any list of companies or products and any figures are complete and/or error free; and/or that (2) any products included in the figures and tables are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion of any products in this report, particularly in any of the figures and tables listed on pages 21-23, 25-27 & 36-43, does not furthermore imply any approval by WHO of these products (which is the sole prerogative of national authorities).

The lists of RDTs included in this report are not exhaustive lists of Visceral Leishmaniasis RDTs. Such lists reflect those products which have been submitted for evaluation. The fact that certain products are not included in the lists and figures included in this report means that they have not or not yet been submitted for evaluation and does not indicate anything in respect of such products' performance.

WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of or in connection with the procurement, distribution and use of any product whatsoever included in this report and the figures and tables listed on pages 21-23, 25-27 & 36-43.

Web version only
Cover design: Lisa Schwarb

Acknowledgements

The evaluation described in this report was a joint project of WHO/TDR and nine test evaluation centres around the world. The project was financed by TDR with technical support from the Prince-Leopold Institute of Tropical Medicine (ITM), Belgium and the Royal Tropical Institute (KIT), Netherlands. The report was prepared by Emily Adams (KIT), Epcó Hasker (ITM) and Jane Cunningham (WHO/TDR).

WHO/TDR wishes to acknowledge the efforts of lead investigators (*) and the staff at all the participating evaluation centres:

Rajendra Memorial Research Institute of Medical Sciences, India	Pradeep Das* S. Bimal A.K. Gupta
Laboratório de Soroepidemiologia e Imunobiologia Instituto de Medicina Tropical de São Paulo, Brazil	Hiro Goto* Beatriz Julieta Celeste Jose Angelo Lauletta Lindoso Anamaria Mello Miranda Paniago Maria Sanchez
Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Fiocruz, Brazil	Ana Rabello* Tália Machado de Assis Edward Oliveira Dorcas Lamounier Costa ^a
B P Koirala Institute of Health Sciences, Nepal	Suman Rijal* Basudha Khanal Murari L Das
Kenya Medical Research Institute (KEMRI), Kenya	Margaret Mbuchi* Monique Wasunna* Charles G. Magiri Alfred M. Muia
Parasitology Laboratory, International Centre for Diarrhoeal Disease Research, Bangladesh	Dinesh Mondal* Khondaker Rifat Hasan Bhaskar Mamun Huda Mukidul Hassan Afrad
University of Khartoum, Sudan	Sayda El Safi* Al Farazdag Saad Nuha Galal Osman Salih Osman Awad Hammad Ahmed Al Mustafa Bashir
Institute Endemic Diseases, University of Khartoum, Sudan	Maowia Mukhtar* Sahar M. Bakhiet Mohamed Osman Hussien Aymen Awad
Institute of Medical Sciences, Banaras Hindu University, India	Shyam Sundar* Dinesh Kumar Prajapati Kamlesh Gidwani Puja Tiwary

^a Maternal and Childhood Department, Federal University of Piauí

WHO/TDR is grateful for the cooperation exhibited by the manufacturers of VL rapid diagnostic tests who agreed to the external and independent evaluation of their products.

WHO/TDR also wishes to acknowledge all those who contributed to protocol development, site assessments, site monitoring, conduct of the evaluation, data analysis and/or preparation of this report:

Olivia Achonduh	University of Yaoundé , Cameroon
Emily Adams	Royal Tropical Institute (KIT), The Netherlands
Marleen Boelaert	Institute of Tropical Medicine (ITM), Belgium
Carmen Canavate	WHO Collaborating Centre for Leishmaniasis, Spain
Jane Cunningham	Special Programme for Research and Training in Tropical Diseases (TDR), Switzerland
Varalakshmi Elango	Consultant (GCLP, Monitoring)
Hashim Ghalib	Special Programme for Research and Training in Tropical Diseases (TDR), Switzerland
Kamlesh Gidwani	Banaras Hindu University (BHU), India
Epcu Hasker	Institute of Tropical Medicine (ITM), Belgium
Diane Jacquet	Institute of Tropical Medicine (ITM), Belgium
Joris Menten	Institute of Tropical Medicine (ITM), Belgium
Francis Moussy	Special Programme for Research and Training in Tropical Diseases (TDR), Switzerland
Rosanna Peeling	London School of Hygiene and Tropical Medicine, United Kingdom
Nidia Rizzo	Universidad del Valle de Guatemala, Guatemala
Gerard Schoone	Royal Tropical Institute (KIT), The Netherlands

Abbreviations

BHU	Banaras Hindu University
CL	Cutaneous leishmaniasis
DAT	Direct Agglutination Test
EA	East Africa
GCLP	Good Clinical Laboratory Practice
GCP	Good Clinical Practice
HEC	Healthy endemic control
HIV	Human immunodeficiency virus
ICT	Immunochromatographic tests
ID	Identification number
ISC	Indian subcontinent
ITM	Institute Tropical Medicine
KIT	Royal Tropical Institute
LN	Lymph node
QA	Quality assurance
RDT	Rapid diagnostic test
rK 39	Recombinant antigen 39
rKE 26	Recombinant antigen 26
RFA	Request for applications
SA	South America
SOP	Standard Operating Procedure
TDR	Special Programme for Research and Training in Tropical Diseases
VL	Visceral Leishmaniasis
VL-LN	Visceral Leishmaniasis Laboratory Network
WHO	World Health Organization

Contents

Executive Summary	7
1. Introduction	9
2. Objectives	10
3. Evaluation methodology	11
3.1 Selection of evaluation centres	11
3.2 Test Selection	12
3.3 Sample size calculations.....	13
3.4 Sample selection	13
3.5 Blinding	13
4. Evaluation Site Preparation	14
4.1 Ethical considerations	14
4.2 Laboratory efficiency	14
4.3 Proficiency testing.....	14
4.4 Evaluation panel composition	14
5. The Evaluation.....	15
5.1 Preparatory phase.....	15
5.1.1 RDT shipments	15
5.1.2 Registration and storage at testing sites	15
5.2 Performing Rapid Diagnostic Tests	15
5.2.1 Evaluation panel.....	15
5.2.2 Thermal stability	17
5.2.3 Ease of use description	17
5.2.4 Reproducibility.....	17
5.2.5 Modification to RDT procedures.....	17
5.3 Data management and analysis.....	17
5.4 Quality Assurance	18
6. Results	19
6.1 Summary of results	19
6.2 Sample characteristics	19
6.2.1 Direct Agglutination Test	19
6.2.2 HIV status	19
6.2.3 Age of patients	19
6.2.4 RDT performance: Sensitivity and specificity	19
6.2.5 Variation in test performance in centres within the same region	24
6.2.6 Band intensity	24
6.3 Thermal stability	24
6.4 Ease of use description	24
6.5 Reproducibility.....	26
7. Discussion.....	28
8. Conclusions	32

Annexes

- A1.1 Characteristics of Visceral Leishmania Rapid Diagnostic Tests included in the evaluation
- A2.0 Sample size per evaluation centre
- A2.1a Sensitivity (with 95% confidence intervals) of RDTs by centre in East Africa
- A2.1b Specificity (with 95% confidence intervals) of RDTs by centre in East Africa
- A2.2a Sensitivity (with 95% confidence intervals) of RDTs by centre in Brazil
- A2.2b Specificity (with 95% confidence intervals) of RDTs by centre in Brazil
- A2.3a Sensitivity (with 95% confidence intervals) of RDTs by centre on the Indian subcontinent
- A2.3b Specificity (with 95% confidence intervals) of RDTs by centre on the Indian subcontinent
- A3.1a. Distribution of band intensity scores against VL positive samples from East Africa
- A3.1b Distribution of band intensity scores against VL positive samples from Brazil
- A3.1c Distribution of band intensity scores against VL positive samples from Indian subcontinent
- A4.1 Run-to run-variability scores for RDTs by region
- A5.1 Operator-to-operator variability scores for RDTs per region
- A6.1 Ease of use description form

Executive Summary

Visceral Leishmaniasis (VL) is one of the world's most neglected diseases, affecting the poorest people in developing countries. Some 500,000 new cases occur annually with 90% of all VL cases in the Indian subcontinent (Bangladesh, India, Nepal), Sudan, Ethiopia and Brazil. Leishmaniasis is a poverty-related disease associated with malnutrition, weakness of the immune system, displacement, poor housing, illiteracy, gender discrimination, and lack of resources.

Up until the 1990s, accurate VL diagnosis necessitated parasitological confirmation by microscopy or culture of the blood, bone-marrow, lymph nodes or spleen. The invasiveness and potentially fatal complications associated with splenic aspiration motivated the development of non-invasive serological tests such as direct agglutination test (DAT) and immunochromatographic lateral-flow assays, commonly referred to as rapid diagnostic tests (RDT).

Enthusiasm and rapid uptake of RDTs for VL, particularly in the Asian region, has translated into the emergence of several commercialized tests targeting serum antibodies to rK39 and other antigens, e.g. rKE 16. However, there are few head-to-head evaluations of diagnostic accuracy for these tests. Therefore, in collaboration with clinicians and laboratory scientists in endemic regions, TDR coordinated a multicentre and multiregional comparative evaluation of commercially available antibody-detecting RDTs to inform country policy. This report describes the performance of four commercially available rK39 and rKE16 antibody detecting RDTs in three global regions of VL endemicity (Indian subcontinent (ISC), East Africa (EA), South America (SA)) using well characterized panels of human sera; a fifth RDT was evaluated in the ISC.

VL RDT Evaluation Programme

All companies manufacturing RDTs for VL under license ISO-13485 Quality System Standard or US FDA 21 CFR were invited to submit tests for evaluation; 4 responded to the call contributing 5 products in total. This report describes the performance of these five commercially available rK39 and rKE16 antibody detecting RDTs. Nine laboratories were chosen in three global endemic regions; namely ISC (n=4), South

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28671

